Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$25.50 USD
-0.40 (-1.54%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $25.50 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 121 - 140 ( 715 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Nov. Prelim Sales: EXPAREL Rebounds Amid Recovery of Elective Surgery Market
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
October Preliminary Net Product Sales: Growth Momentum Picking Back Up
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
3Q21: Record Operating Margin Despite Depressed Sales Speaks Volumes; PCRX Sees 4Q Exparel Rebound; PT Up to $86
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q3: EXPAREL Pushing Past Pandemic Headwinds, Rebound Expected in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Investor Day Showcases EXPAREL''s Blockbuster Potential,iovera''s Future Growth
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Opportunistic Strike; Flexion Acquisition Brings Complementary Growth Driver at Good Value; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Flexion Acquisition Adds ZILRETTA to Neural Pain Portfolio; Q3 Prelim Sales
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Imitation is the Highest Form of Flattery: Pacira Defends EXPAREL from Generics
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L